Wave Life Sciences Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Wave Life Sciences şirketinin toplam hissedar öz sermayesi $149.5M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $358.5M ve $209.0M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$310.95m
Eşitlik	US$149.51m
Toplam yükümlülükler	US$208.99m
Toplam varlıklar	US$358.50m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 1U5 'nin kısa vadeli varlıkları ( $324.5M ) kısa vadeli yükümlülüklerini ( $170.7M ) aşıyor.

Uzun Vadeli Yükümlülükler: 1U5 şirketinin kısa vadeli varlıkları ( $324.5M ) uzun vadeli yükümlülüklerini ( $38.3M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 1U5 borçsuzdur.

Borcun Azaltılması: 1U5 un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 1U5 şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: 1U5 serbest nakit akışı her yıl % { 5.3 1.9 |round(1)}} yıl boyunca yeterli nakit akışına sahip olacaktır.

Wave Life Sciences Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Third quarter 2024 earnings released: US$0.47 loss per share (vs US$0.066 profit in 3Q 2023)

Wave Life Sciences Ltd. has filed a Follow-on Equity Offering in the amount of $250 million.

Wave Life Sciences Ltd. to Report Q3, 2024 Results on Nov 12, 2024

Wave Life Sciences Ltd. Announces First-Ever Therapeutic RNA Editing in Humans Achieved in RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency

New major risk - Shareholder dilution

Wave Life Sciences Ltd. has completed a Follow-on Equity Offering in the amount of $200.000004 million.

Wave Life Sciences Ltd. has completed a Follow-on Equity Offering in the amount of $131.97401 million.

Wave Life Sciences Ltd. Announces Positive Interim Data from Forward-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping

Wave Life Sciences Receives FDA Rare Pediatric Disease Designation for WVE-N531 for the Treatment of Duchenne Muscular Dystrophy

Second quarter 2024 earnings released: US$0.25 loss per share (vs US$0.20 loss in 2Q 2023)

Wave Life Sciences Ltd. Announces Positive Results from Phase 1b/2a Select-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington's Disease

Wave Life Sciences Ltd., Annual General Meeting, Aug 06, 2024

New major risk - Revenue and earnings growth

Wave Life Sciences Announces Appointment of Erik Ingelsson as Chief Scientific Officer

First quarter 2024 earnings released: US$0.24 loss per share (vs US$0.27 loss in 1Q 2023)

Wave Life Sciences Ltd. to Report Q1, 2024 Results on May 09, 2024

Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency

Full year 2023 earnings released: US$0.54 loss per share (vs US$2.05 loss in FY 2022)

New major risk - Revenue and earnings growth

Wave Life Sciences Ltd. to Report Q4, 2023 Results on Mar 06, 2024

Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy

Wave Life Sciences Ltd. has completed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Share price stability

Wave Life Sciences Ltd. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Financial position

Third quarter 2023 earnings released: EPS: US$0.071 (vs US$0.41 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Wave Life Sciences Ltd. to Report Q3, 2023 Results on Nov 09, 2023

Wave Life Sciences Ltd. Announces Submission of First Clinical Trial Application for Wve-006

New major risk - Share price stability

Second quarter 2023 earnings released: US$0.20 loss per share (vs US$0.62 loss in 2Q 2022)

Wave Life Sciences Ltd. to Report Q2, 2023 Results on Aug 03, 2023

Wave Life Sciences Announces Topline Results from Phase 1B/2A Focus-C9 Study of WVE-004 for C9orf72-Associated Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

President recently sold €111k worth of stock

Wave Life Sciences Provides Positive Update on Proof-Of-Concept Study for Wve-N531 in Duchenne Muscular Dystrophy

Wave Life Sciences Ltd. announced that it expects to receive $50 million in funding from GSK plc

Wave Life Sciences Ltd. announced that it expects to receive $50 million in funding from GSK plc

Insufficient new directors

Insufficient new directors

Insufficient new directors

Wave Life Sciences Ltd. Announces Management Changes

Wave Life Sciences Announces Positive Update from Phase 1b/2a SELECT-HD Trial with Initial Results Indicating Allele-Selective Target Engagement with WVE-003 in Huntington’s Disease

Wave Life Sciences Ltd., Annual General Meeting, Aug 09, 2022

Wave Life Sciences Ltd.(NasdaqGM:WVE) dropped from Russell 2000 Dynamic Index

Wave Life Sciences Ltd. Announces First Clinical Data from Ongoing Focus-C9 Trial of Wve-004 for C9-Als and C9-Ftd

Wave Life Sciences Announces Publication of Foundational Preclinical Data Supporting Development of WVE-004 for C9orf72-associated ALS and FTD

Wave Life Sciences Ltd. Announces Positive Update to Ongoing Phase 1b/2a FOCUS-C9 Study by Potent, Durable Reductions of Poly(GP) with Low, Single Doses of WVE-004

Wave Life Sciences Ltd. Announces Nature Biotechnology Publication Highlighting First RNA Base Editing in Non-Human Primates Using an Endogenous Enzyme

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

President recently sold €68k worth of stock

Third quarter 2021 earnings released: US$0.12 loss per share (vs US$0.86 loss in 3Q 2020)

Wave Life Sciences Announces New Data for Leading RNA Editing Capability Across Multiple Tissues

Wave Life Sciences Announces Initiation of Dosing in Phase 1b/2a SELECT-HD Clinical Trial of WVE-003 in Huntington’s Disease

First half 2021 earnings released: US$1.65 loss per share (vs US$2.53 loss in 1H 2020)

Wave Life Sciences Ltd. Announces Proof-of-Concept Preclinical Data for Adar Editing Program in Alpha-1 Antitrypsin Deficiency

Full year 2020 earnings released: US$3.82 loss per share (vs US$5.72 loss in FY 2019)

Revenue misses expectations

New 90-day high: €8.35

Wave Life Sciences Ltd. Announces Key Upcoming Milestones for 2021 and Continued Advancement of Proprietary Discovery and Drug Development Platform

Wave Life Sciences Ltd. Announces Resignation of Amy Pott from the Board and the Compensation Committee

New 90-day high: €7.70

Wave Life Sciences Ltd. Announces Management Changes

Wave Life Sciences Announces Appointment of Jonathan Rosin as Chief Human Resources Officer

Revenue misses expectations

Third quarter 2020 earnings released: US$0.86 loss per share

New 90-day low: €6.50

New 90-day low: €6.95

New 90-day high - €11.20

New 90-day low - €7.20

First half earnings released

Wave Life Sciences Ltd.(NasdaqGM:WVE) dropped from S&P Pharmaceuticals Select Industry Index

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi